ORAL-CONTRACEPTIVE USE AND RISK OF CUTANEOUS MALIGNANT-MELANOMA IN A CASE-CONTROL STUDY OF FRENCH WOMEN

被引:33
作者
LE, MG
CABANES, PA
DESVIGNES, V
CHANTEAU, MF
MLIKA, N
AVRIL, MF
机构
关键词
CASE-CONTROL STUDY; FRANCE; MALIGNANT MELANOMA; ORAL CONTRACEPTIVES;
D O I
10.1007/BF00124252
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We report the results of a case-control study designed to analyze the relationship between oral contraceptive use (OC) and the risk of cutaneous malignant melanoma (MM) in 240 White women under the age of 45. Five French centers participated in the study between February 1982 and january 1987 for periods of eight to 54 months, depending on the center. Cases were 91 consecutive newly diagnosed patients with histologically verified MM. Each case was matched with one or two controls on year of birth, date of interview, and-treatment center. Controls were 149 patients with either malignant or nonmalignant disease who came to the center for diagnosis and treatment. Odds ratios (OR) were estimated by multivariate analyses taking into account age at menarche, sunlight exposure, and skin characteristics. No significant relation was found between the risk of MM and the total duration of OC use, age at start of use, and elapsed time since the first OC use. However, when the analysis was restricted to women aged 30-40 years, i.e., those who were able to use OC for 10 years or more, or who had started OC use 15 years or more before the diagnosis, the risk of MM increased significantly with the duration of OC use (P = 0.03). A total of more than 4,000 hours of sunlight exposure, and menarche before the age of 14 also were found to increase significantly the risk of MM (OR = 5.4, 95 percent confidence interval [CI] = 1.6-18.3; and OR = 3.6, CI = 1.0-12.5, respectively).
引用
收藏
页码:199 / 205
页数:7
相关论文
共 21 条
[1]  
Snell R.S., Bischitz P.G., The effect of large doses of estrogen and estrogen and progesterone on melanin pigmentation, J Invest Dermatol, 35, pp. 73-82, (1960)
[2]  
Fisher R.I., Neifeld J.P., Lippman M.E., Estrogen receptors in human malignant melanoma, Lancet, 2, pp. 337-8, (1976)
[3]  
Creagan E.T., Ingle J.N., Woods J.E., Pritchard D.J., Jiang N.S., Estrogen receptors in patients with malignant melanoma, Cancer, 46, pp. 1785-6, (1980)
[4]  
Avril M.F., Delarue J.C., Prade M., Récepteurs oestrogéniques et progestéroniques dans les mélanomes malins, les naevi pigmentaires bénins et les épithéliomas basocellulaires, Pathol Biol, 33, pp. 39-44, (1985)
[5]  
Flowers J., Seigler H., MacCarty, Konrath J., MacCarty K., Absence of estrogen receptor in human melanoma as evaluated by a monoclonal antiestrogen receptor antibody, Arch Dermatol, 123, pp. 764-5, (1987)
[6]  
Karakousis C.P., Lopez R.E., Bhakoo H.S., Rosen F., Hoore R., Carlson M., Estrogen and progesterone receptors and Tamoxifen in malignant melanoma, Cancer Treat Rep, 64, pp. 819-27, (1980)
[7]  
Beral V., Ramcharan S., Faris R., Malignant melanoma and oral contraceptive use among women in California, Br J Cancer, 36, pp. 804-9, (1977)
[8]  
Adam S.A., Sheaves J.K., Wright N.H., Mosser R.W., Vessey M.P., A case-control study of the possible association between oral contraceptives and malignant melanoma, Br J Cancer, 44, pp. 45-50, (1981)
[9]  
Kay C.R., Malignant melanoma and oral contraceptive (Letter), British Journal of Cancer, 44, (1981)
[10]  
Bain C., Hennekens C.H., Speizer F.E., Rosner B., Willett W., Belanger C., Oral contraceptive use and malignant melanoma, JNCI, 68, pp. 537-9, (1982)